Kalle Levon

Kalle Levon

Auto-generated profile, based on publicly available information

Kalle Levon

Department of Chemical and Biomolecular Engineering, NYU Tandon School of Engineering., NY, NY

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2010 in Macromolecular Chemistry and Physics
Verified
Journal Article
Closed access
PDF file
SGShilpi Gupta
Shilpi Gupta
Mukesh PandeyMukesh Pandey
Mukesh Pandey
KLKalle Levon
Kalle Levon
RHRainer Haag
Rainer Haag
AWArthur C. Watterson
Arthur C. Watterson
Sunil SharmaSunil Sharma
Sunil Sharma

1 February 2021 in Journal of Neuroscience Methods
Verified
Journal Article
Open access
LHLaura Honkamäki
Laura Honkamäki
TJTiina Joki
Tiina Joki
NGNikita A. Grigoryev
Nikita A. Grigoryev
KLKalle Levon
Kalle Levon
LYLaura Ylä-Outinen
Laura Ylä-Outinen
SNSusanna Narkilahti
Susanna Narkilahti
Three-dimensional (3D) in vitro models have been developed into more in vivo resembling structures. In particular, there is a need for human-based models for neuronal tissue engineering (TE). To produce such a model with organized microenvironment for cells in central nervous system (CNS), a 3D layered scaffold composed of hydrogel and cell guiding fibers has been proposed. Here, we describe a novel method for producing a layered 3D scaffold consisting of electrospun poly (L,D-lactide) fibers embedded into collagen 1 hydrogel to achieve better resemblance of cells' natural microenvironment for human pluripotent stem cell (hPSC)-derived neurons. The scaffold was constructed via a single layer-by-layer process using an electrospinning technique with a unique collector design. The method enabled the production of layered 3D cell-containing scaffold in a single process. HPSC-derived neurons were found in all layers of the scaffold and exhibited a typical neuronal phenotype. The guiding fiber layers supported the directed cell growth and extension of the neurites inside the scaffold without additional functionalization. Previous methods have required several process steps to construct 3D layer-by-layer scaffolds. We introduced a method to produce layered 3D scaffolds to mimic the cell guiding cues in CNS by alternating the soft hydrogel matrix and fibrous guidance cues. The produced scaffold successfully enabled the long-term culture of hPSC-derived neuronal cells. This layered 3D scaffold is a useful model for in vitro and in vivo neuronal TE applications.

1 January 1995 in Polymers for Advanced Technologies
Verified
Journal Article
Closed access
PDF file
YLYun‐Hsin Liao
Yun‐Hsin Liao
KLKalle Levon
Kalle Levon

24 December 2021 in Blood
Verified
Journal Article
Open access
JRJEANFRANCOIS ROSSI
JEANFRANCOIS ROSSI
HCHao-Chun Chiang
Hao-Chun Chiang
ZLZhaoyang Lu
Zhaoyang Lu
KLKalle Levon
Kalle Levon
FRFrits Van Rhee
Frits Van Rhee
BKBernard Klein
Bernard Klein
Dysregulated inflammatory responses are characterized by inappropriate levels of inflammatory markers, speed of generation, degree, and major site of production, such as a vital organ. COVID-19 severity and mortality are strongly associated with interleukin (IL)-6 levels. High IL-6 levels are also observed in idiopathic Multicentric Castleman Disease (iMCD). Previously, we developed the first anti-IL-6 monoclonal antibody (mAb) treatments and showed that C-reactive protein (CRP) production could be fully controlled by IL-6 in humans. Using mathematical modeling, with CRP as an IL-6 surrogate marker, we predicted the ability of an anti-IL-6 mAb to block plasma IL-6 activity and showed IL-6 inhibition was dependent on the extent of whole-body IL-6 production. We postulate that in patients (pts) in whom IL-6 concentration at the site of inflammation is higher than in the plasma, full blockade of plasma IL-6 activity, shown by complete CRP inhibition, is the minimum requirement to achieve clinical efficacy. CRP inhibition with tocilizumab (TCZ) in pts with COVID-19. We identified 35 published studies evaluating the efficacy or potential role of anti-IL-6 therapy in pts with severe COVID-19. Surprisingly, only one (Luo et al. J Med Virol 2020;92:814) reported dynamics of CRP reduction for individual patients throughout treatment. We fitted a hypothetical curve of CRP reduction required to completely block IL-6, based on the half-life of CRP, and added data points of CRP serum levels from pts treated with anti-IL-6 receptor (IL-6R) therapy, TCZ, in this study. Complete reduction of CRP was not achieved in all patients: 3 pts who died had CRP levels ≥12.8 mg/l. Of 2 pts whose disease worsened, CRP levels were 93.5 mg/l and 6.3 mg/l. However, pts whose condition stabilized (n=9), or whose symptoms improved (n=1), had CRP levels close to the theoretical curve that is likely required to fully block IL-6 (CRP levels ≤5.0 mg/l). Half of these pts had been given repeated doses of TCZ. Siltuximab (SIL) treatment (NCT01024036 trial) for pts with iMCD. To assess the impact of baseline CRP levels on response to anti-IL-6 therapy, SIL, patients were divided into low and high CRP groups based on a baseline CRP level threshold of 40 mg/l (corresponding to ~40 pg/ml of IL-6; Fig 1). In patients with low baseline CRP levels (40 mg/l; n=17), CRP levels were significantly reduced on day 8 (n=17; P<0.0001) and day 15 (n=15; P<0.0001) post-dosing (Fig 1). A significant increase in CRP levels from day 8 to day 15 was observed in these patients (P=0.0120); this increase was not observed in patients with low baseline CRP levels (P=0.243; Fig 1). There was a negative correlation between maximum CRP and hemoglobin change (P<0.001). Inhibition of IL-6 activity by anti-IL-6 (SIL 700 mg) and anti-IL-6R (TCZ 800 mg) as monotherapy, intensified, or combined therapy. To evaluate the effect of therapy on IL-6 activity, our algorithm modeled inhibition of IL-6-(IL-6R/soluble IL-6R)-gp130 transducer complexes. This serves as a proxy for IL-6 bioactivity and accounts for the buffering capacity of gp130, which can be overwhelmed in inflammatory situations with high IL-6 concentrations. Due to uncertainty over the concentration of mAbs in alveoli relative to plasma, we modeled the effects of SIL and TCZ at local concentrations of 100%, 10%, and 1% (Fig 2) of those in plasma. Our model demonstrated that anti-IL-6 was associated with stronger inhibition of CRP than anti-IL-6R. However, only the association of both anti-IL-6 and anti-IL-6R mAbs was associated with a total blockade of CRP, which is probably necessary when IL-6 levels are associated with high risk to the patient. Different administration schedules to intensify anti-IL-6 therapy were modeled, including the repeated or combined use of anti-IL-6 and anti-IL-6R mAbs. The results form a basis to optimize treatment strategies to avoid the cytokine storm in several diseases, including cancer, iMCD, and autoimmune disorders. The feasibility of the theoretically defined approaches needs to be evaluated, particularly the potential side-effect profile for a combined treatment approach. In conclusion, in clinical practice, IL-6 inhibition should be individualized based on pathophysiology and regular CRP monitoring.

20 December 2006
Verified
Book Chapter
Closed access
YZYanxiu Zhou
Yanxiu Zhou
BYBin Yu
Bin Yu
KLKalle Levon
Kalle Levon

1 January 2008 in Journal of Long-Term Effects of Medical Implants
Verified
Journal Article
Closed access
KLKalle Levon
Kalle Levon
Laughter from a facial-bone-cancer patient is a good indication of the success with stem cell engineering. Facial reconstruction with the use of stem cells (SCs) made a Finnish man able to eat, speak, and smile again. Similarly, a pleasant sigh from a heart attack patient in Germany exhibited improved blood circulation after SC treatment. Such great news attracts more and more students to the field of bioinformatics to learn about signaling pathways. Similarly, students eagerly attend tissue engineering courses to learn the parameters affecting SC growth and differentiation. Curiosity of this order is an essential emotion that drives learning. It is important to encourage individual expression and opinion in our educational systems and to teach the respect for diversity in ethical thinking. Our experience is based on several years of teaching bioinformatics and tissue engineering courses, and addressing ethical issues in an individual essay format. This emphasizes the uniqueness of individual learning and builds the pathway for building personal skills. The excitement with the expression of personal views in critical issues is a good assessment for education in our learning society.